Learning versus confirming in clinical drug development*
- 10 March 1997
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 61 (3) , 275-291
- https://doi.org/10.1016/s0009-9236(97)90160-0
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New ZealandJournal of Neurosurgery, 1996
- ESTIMATING THE MINIMUM THERAPEUTICALLY EFFECTIVE DOSE OF A COMPOUND VIA REGRESSION MODELLING AND PERCENTILE ESTIMATIONStatistics in Medicine, 1995
- Trimetrexate: A Critical Appraisal of the Phase II Clinical Trial Experience: Evidence of Drug Discovery-Clinical Development DisjunctionCancer Investigation, 1994
- Theophylline Target Concentration in Severe Airways Obstruction - 10 or 20 mg/L?Clinical Pharmacokinetics, 1993
- Time and Theophylline Concentration Help Explain the Recovery of Peak Flow Following Acute Airways ObstructionClinical Pharmacokinetics, 1993
- Bayesian methods for phase I clinical trialsStatistics in Medicine, 1992
- A simulation study comparing designs for dose rangingStatistics in Medicine, 1991
- Experimental design for drug development: a bayesian approachJournal of Biopharmaceutical Statistics, 1991
- Use and Abuse of RegressionTechnometrics, 1966